Form 4: Aligos Therapeutics Director Granted Stock Options

Aligos Therapeutics, Inc. Director Margarita Chavez was granted 5,860 stock options with an exercise price of $7.63, vesting by mid-2026.

Summary

• Margarita Chavez, a Director of Aligos Therapeutics, Inc. (ALGS), was granted stock options.
• The grant consists of 5,860 stock options, each representing the right to buy one share of Common Stock.
• The exercise price for these options is $7.63 per share.
• The transaction date for this grant was June 25, 2025.
• The options have an expiration date of June 25, 2035.
• The shares subject to the option will vest and become exercisable as to 100% of the total number of shares on the earlier of the first anniversary of the grant date (June 25, 2026) or immediately prior to the annual meeting in 2026 of the Issuer's stockholders, subject to continuous service.

Sentiment

Score: 7

Explanation: The document reports a standard, positive event of director compensation through stock options, which aligns management interests with shareholders. It does not contain any negative or unexpected information.

Positives

• The grant of stock options to a director aligns their financial interests with those of the shareholders, incentivizing long-term value creation.
• This is a standard form of compensation for board members, indicating stable corporate governance practices.

Risks

• The value of the stock options is dependent on the future market price of Aligos Therapeutics, Inc. common stock; if the stock price does not exceed the exercise price of $7.63, the options may expire worthless.
• Vesting of the options is contingent upon Margarita Chavez's continuous service to the Issuer through the vesting date.

Future Outlook

The stock options are designed to incentivize the director's continued service and align their interests with the company's long-term performance, with vesting contingent on continuous service through mid-2026.

Industry Context

The granting of stock options to directors is a common practice in the biotechnology and pharmaceutical industries, serving as a key component of executive and board compensation packages to attract and retain talent and align interests with long-term shareholder value.

Comparison to Industry Standards

• The practice of granting stock options to non-employee directors is a widely accepted compensation method across the biotechnology and pharmaceutical sectors, similar to practices observed at companies like Gilead Sciences, Amgen, or Moderna, which frequently use equity-based awards to compensate their board members.
• The vesting schedule, tied to continued service and an annual meeting, is a standard mechanism to ensure ongoing commitment and engagement from board members, consistent with corporate governance best practices in the industry.

Stakeholder Impact

• Shareholders: The grant of stock options to a director can be viewed positively as it aligns the director's financial incentives with the company's stock performance, potentially leading to better long-term decision-making.
• Employees: While not directly impacting employees, such compensation practices are part of the overall corporate governance and compensation structure that can influence company culture and performance.
• Director (Margarita Chavez): This grant provides a significant incentive and potential future financial benefit, contingent on the company's stock performance and her continued service.

Next Steps

• Margarita Chavez's stock options are expected to vest on the earlier of June 25, 2026, or immediately prior to Aligos Therapeutics' 2026 annual meeting, subject to continuous service.
• Following vesting, Margarita Chavez will have the right to exercise the options to purchase 5,860 shares of Aligos Therapeutics Common Stock at $7.63 per share until the expiration date of June 25, 2035.

Key Dates

Recommendation

Keywords

Aligos Therapeutics, ALGS, Stock Option, Director Compensation, SEC Form 4, Insider Transaction, Equity Grant, Beneficial Ownership